Developing a Novel, Oral Resolvin-based Therapeutic
for Chronic Inflammatory Diseases and Cancer
Thetis is a clinical stage biopharmaceutical company developing a first-in-class, oral Resolvin E1 drug (TP-317) for treating mild-to-moderate inflammatory bowel disease (IBD) and solid tumors.
Novel Mechanism
Resolvin E1 (RvE1) is a partial agonist of BLT1, a GPCR expressed on diverse immune cells, to promote innate and adaptive immunity to restore immune homeostasis.
Safety Premium
Based on clinical safety data with oral RvE1, TP-317 is anticipated to be safe and well tolerated.
Differentiation
As an oral small molecule agonist of BLT1, TP-317 activates the pro-repair and anti-tumoral biology of BLT1 without the unwanted effects produced by LTB4 activation of BLT1.
Pipeline Indications
A Phase 1 study in healthy volunteers will be completed in 2024. Patient studies in mild-to-moderate IBD and solid tumor cancers are planned for 2025.
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration.
